In a regulatory filing, Cytokinetics (CYTK) president and CEO Robert Blum disclosed the sale of 15,000 common shares of the company on March 31 ...

Cytokinetics' chief executive, Robert Blum, said the new deal with Royalty Pharma “reinforces our shared conviction in the value of our cardiac myosin-focused pipeline of drug candidates.” ...

Cytokinetics should hear back from the FDA ... In the company's third-quarter results update, chief executive Robert Blum said that aficamten has a "next-in-class safety and efficacy profile ...

Vanguard Group Inc. raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.3% in the ...

Franklin Resources Inc. boosted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The firm owned 545,813 shares of ...

Cytokinetics (CYTK) shares rallied 5.4% in the last trading session to close at $45.43. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Cytokinetics (NASDAQ:CYTK) added ~10% in the premarket on Wednesday after its rival Edgewise Therapeutics (NASDAQ:EWTX) posted topline data from a mid-stage trial for EDG-7500, an experimental ...

In this article, we are going to look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market ...